文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

亚砷酸-铂（II）抗癌配合物水溶液的稳定结构与反应活性

Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes.

作者信息

Miodragović Đenana U, Quentzel Jeremy A, Kurutz Josh W, Stern Charlotte L, Ahn Richard W, Kandela Irawati, Mazar Andrew, O'Halloran Thomas V

机构信息

Chemistry of Life Processes Institute and Department of Chemistry, Northwestern University, 2145 Sheridan Road, Evanston, IL 60208 (USA) http://www.chemistry.northwestern.edu/faculty/thomas-ohalloran.html.

出版信息

Angew Chem Int Ed Engl. 2013 Oct 4;52(41):10749-52. doi: 10.1002/anie.201303251. Epub 2013 Aug 22.

DOI:10.1002/anie.201303251
PMID:24038962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3932145/
Abstract

The first molecular adducts of platinum and arsenic based anticancer drugs - arsenoplatins - show unanticipated structure, substitution chemistry, and cellular cytotoxicity. The Pt-As bonds in these complexes are stable in aqueous solution and strongly influence the lability of the ligand.

摘要

铂和砷基抗癌药物的首个分子加合物——砷铂化合物——展现出意想不到的结构、取代化学性质及细胞毒性。这些络合物中的铂-砷键在水溶液中稳定，且对配体的活性有强烈影响。

相似文献

[1]
Robust structure and reactivity of aqueous arsenous acid-platinum(II) anticancer complexes.

Angew Chem Int Ed Engl. 2013-10-4

[2]
Potent anticancer activity and possible low toxicity of platinum(II) complexes with functionalized 1,1-cyclobutanedicarboxylate as a leaving ligand.

Chemistry. 2014-11-10

[3]
Mixed ligand complexes of platinum(II) and palladium(II) with cytokinin-derived compounds Bohemine and Olomoucine: X-ray structure of [Pt(BohH+-N7)Cl(3)].9/5H2O [Boh=6-(benzylamino)-2-[(3-(hydroxypropyl)-amino]-9-isopropylpurine, Bohemine].

J Inorg Biochem. 2003-4-1

[4]
Design, Synthesis of Novel Platinum(II) Glycoconjugates, and Evaluation of Their Antitumor Effects.

Chem Biol Drug Des. 2016-6

[5]
Homo- and heteroleptic Pt(II) complexes of ONN donor hydrazone and 4-picoline: A synthetic, structural and detailed mechanistic anticancer investigation.

Eur J Med Chem. 2017-11-26

[6]
Novel oximato-bridged platinum(II) di- and trimer(s): synthetic, structural, and in vitro anticancer activity studies.

Inorg Chem. 2012-6-12

[7]
Anticancer platinum(II) complexes bearing N-heterocycle rings.

Bioorg Med Chem Lett. 2019-3-29

[8]
Morpholine or methylpiperazine and salicylaldimine based heteroleptic square planner platinum (II) complexes: In vitro anticancer study and growth retardation effect on E. coli.

Eur J Med Chem. 2017-5-5

[9]
Target-selective delivery and activation of platinum-based anticancer agents.

Future Med Chem. 2015

[10]
trans-Dichloridopalladium(II) and platinum(II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: synthesis, structural characterization, DNA binding and in vitro cytotoxicity studies.

Eur J Med Chem. 2012-12-8

引用本文的文献

[1]
A Tunable Hydrogel Platform Based on Platinum-Containing Polymeric Arsenicals.

Chem Mater. 2025-5-7

[2]
Description of a Non-Canonical AsPt Blue Species Originating from the Aerobic Oxidation of AP-1 in Aqueous Solution.

Int J Mol Sci. 2024-7-5

[3]
An unprecedented palladium-arsenic catalytic cycle for nitriles hydration.

Front Chem. 2023-8-7

[4]
Carbohydrate-conjugated 4-(1,3,2-dithiarsolan-2-yl)aniline as a cytotoxic agent against colorectal cancer.

RSC Adv. 2018-12-5

[5]
Preparation and characterization of erythrocyte membrane cloaked PLGA/arsenic trioxide nanoparticles and evaluation of their anti-tumor effect.

RSC Adv. 2018-6-1

[6]
Current Advances of Nanomedicines Delivering Arsenic Trioxide for Enhanced Tumor Therapy.

Pharmaceutics. 2022-3-30

[7]
Metallodrugs: Mechanisms of Action, Molecular Targets and Biological Activity.

Int J Mol Sci. 2022-3-23

[8]
Arsenic in medicine: past, present and future.

Biometals. 2023-4

[9]
Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study.

Inorg Chem. 2022-2-21

[10]
Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers.

Molecules. 2021-9-6

本文引用的文献

[1]
Trans-platinum/thiazole complex interferes with Sp1 zinc-finger protein.

Angew Chem Int Ed Engl. 2012-12-3

[2]
Redox activation of metal-based prodrugs as a strategy for drug delivery.

Adv Drug Deliv Rev. 2012-1-25

[3]
The status of platinum anticancer drugs in the clinic and in clinical trials.

Dalton Trans. 2010-6-30

[4]
Arsenic trioxide - An old drug rediscovered.

Blood Rev. 2010-5-15

[5]
Targeting mitochondria for cancer therapy.

Nat Rev Drug Discov. 2010-5-14

[6]
Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Science. 2010-4-9

[7]
Coencapsulation of arsenic- and platinum-based drugs for targeted cancer treatment.

Angew Chem Int Ed Engl. 2009

[8]
Arsenic trioxide and cisplatin synergism increase cytotoxicity in human ovarian cancer cells: therapeutic potential for ovarian cancer.

Cancer Sci. 2009-9-2

[9]
Arsenic trioxide exerts synergistic effects with cisplatin on non-small cell lung cancer cells via apoptosis induction.

J Exp Clin Cancer Res. 2009-8-8

[10]
Biological responses to arsenic compounds.

J Biol Chem. 2009-7-10

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索